-
Mashup Score: 1How Electronic Medical Record Integration Can Support More Efficient Critical Care Clinical Trials - 7 month(s) ago
Author links open overlay panel Ankita Agarwal MD, MSc a, Joseph Marion PhD b, Paul Nagy PhD c d, Matthew Robinson MD e, Allan Walkey MD, MSc f, Jonathan Sevransky MD, MHS a • Current challenges to interventional trials and critical care research include an inefficient trial design, heterogenous patient populations, heterogeneous treatment effects, and difficulties with patient enrollment. • Precise phenotyping of critically ill patients may allow more targeted enrollment of patients in critical care
Source: www.sciencedirect.comCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 12
Walmart, Walgreens and other chains are partnering with Big Pharma to enroll customers in medical studies.
Source: www.cnet.comCategories: Cardiologists, Latest HeadlinesTweet-
In an effort to expand #decentralized #trials, pharmaceutical companies are partnering with drugstores in the USA to recruit patients into clinical trials. A step forward in bringing trials to the public, as long as there are checks and balances in place. https://t.co/vBDYmkM1Wb
-
-
Mashup Score: 33Bridging Treatment Implementation Gaps in Patients With Heart Failure: JACC Focus Seminar 2/3 - 9 month(s) ago
Heart failure (HF) is a leading cause of death and disability in older adults. Despite decades of high-quality evidence to support their use, guidelin…
Source: www.sciencedirect.comCategories: Cardiologists, Latest HeadlinesTweet-
We review #implementation strategies proven effective in RCTs, recognizing irony that even they havent been widely implemented We propose a #conceptualframework for implementation Even #phase3 trials can follow this framework for early implementation https://t.co/uTc6iJ9VkV 5/ https://t.co/f0rhYOfcI8
-
Implementation trials should be robustly designed #Cluster designs help avoid contamination Trial execution requires alignment - regulatory - public - institution - infrastructure Fidelity should be measured Outcomes should be meaningful https://t.co/uTc6iJ9VkV 4/ https://t.co/vQ6YIbaXgt
-
#ImpSci: study of strategies that ⬆️ systemic uptake of evidence Guided by #conceptualframeworks, implementation research should -be #embedded in health systems -engage the right stakeholders -be tailored to barriers, facilitators, regional context https://t.co/uTc6iJ9VkV 3/ https://t.co/DldyxajmwH
-
There are #barriers to implementation at multiple levels - trial design - healthcare system - intervention - institution - clinician These must be addressed when we plan #implementation or #deimplementation Important processes to consider👇🏽 https://t.co/uTc6iJ9VkV 2/ https://t.co/Bs1pWIcvY8
-
#Implementation lags years behind #evidence How might we design #trials, engage #stakeholders, & align #healthcare systems for better implementation? We offer strategies & propose a conceptual framework to bridge the evidence-care gap @JACCJournals https://t.co/uTc6iJ9VkV 1/ https://t.co/lOEAaSZ4OK
-
-
Mashup Score: 2
Randomized controlled trials (RCTs) may change the standard of care of patients sharing the characteristics of trial participants. However, well-designed trials
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
RT @BartoszHudzik: Framework for interpretation of superiority results 👉#trials #RCTs with neutral or negative https://t.co/wAukbTpwEg #EB…
-
-
Mashup Score: 0Please wait whilst we redirect you - 10 month(s) ago
About ScienceDirectRemote accessShopping cartAdvertiseContact and supportTerms and conditionsPrivacy policyWe use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.Copyright © 2023 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V.ScienceDirect® is a registered trademark…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Yes- so important to include patients of all races/ethnicities in #clinicaltrials! Honored to be leading this effort for GOG-F. Check out our recent manuscript on improving #IDEA in #trials https://t.co/4ZEOLSX16x @GOG @SGO_org @gyncsm @IGCSociety @acog @AACR @ASCO @AACI_Cancer https://t.co/6Oih3BQ0Ud
-
-
Mashup Score: 4Critical Care Clinical Trialists Workshop - 11 month(s) ago
The 3CT Workshop aims to foster an international exchange of ideas where attendees will brainstorm on trial design, conduct, ethics and data interpretation in the critical care area. The sessions will cover domains including drugs, devices, and biomarkers in the field of intensive care. Following the template of the CVCT workshop, the Critical Care Clinical Trialists (3CT) workshop is a…
Categories: Cardiologists, Latest HeadlinesTweet-
Register for the #CriticalCare Clinical Trialists program Jun 8-10, DC Attend our sessions on #pragmatic, registry-based #trials, #AI / #digitalhealth & more Multistakeholder discussions w #FDA, #NIH, #researchers, #clinicians #HF #Shock @AlexMebazaa https://t.co/kBgymNN0rn https://t.co/9m0ATF8CrD
-
-
Mashup Score: 1Biomarker reduction indicates treatment response to Belimumab - 11 month(s) ago
Dr. Anna Wolska from the Lupus Foundation of America interviews Dr. Andrea Fava from Johns Hopkins University about Belimumab treatment in lupus nephritis. Dr Fava elucidates on the correlation betwee
Source: SoundCloudCategories: Latest Headlines, RheumatologyTweet-
#Lupus #Science & #Medicine and @LupusOrg Dr. Anna Wolska interviews Dr. Andrea Fava from @JohnHopkinsUni1 about #Belimumab treatment in lupus #nephritis. #SLE #Rheumatology #EULAR2023 #LupusNephritis #Treatment #Biomarker #precisionmedicine #trials https://t.co/w4ZzAavQ8F
-
-
Mashup Score: 1Biomarker reduction indicates treatment response to Belimumab - 11 month(s) ago
Dr. Anna Wolska from the Lupus Foundation of America interviews Dr. Andrea Fava from Johns Hopkins University about Belimumab treatment in lupus nephritis. Dr Fava elucidates on the correlation betwee
Source: SoundCloudCategories: Latest Headlines, RheumatologyTweet-
#Lupus #Science & #Medicine and @LupusOrg Dr. Anna Wolska interviews Dr. Andrea Fava from @JohnHopkinsUni1 about #Belimumab treatment in lupus #nephritis. #SLE #Rheumatology #EULAR2023 #LupusNephritis #Treatment #Biomarker #precisionmedicine #trials https://t.co/w4ZzAavQ8F
-
-
Mashup Score: 1Biomarker reduction indicates treatment response to Belimumab - 11 month(s) ago
Dr. Anna Wolska from the Lupus Foundation of America interviews Dr. Andrea Fava from Johns Hopkins University about Belimumab treatment in lupus nephritis. Dr Fava elucidates on the correlation betwee
Source: SoundCloudCategories: Latest Headlines, RheumatologyTweet-
#Lupus #Science & #Medicine and @LupusOrg Dr. Anna Wolska interviews Dr. Andrea Fava from @JohnHopkinsUni1 about #Belimumab treatment in lupus #nephritis. #SLE #Rheumatology #EULAR2023 #LupusNephritis #Treatment #Biomarker #precisionmedicine #trials https://t.co/w4ZzAavQ8F
-
-
Mashup Score: 1Digitalis in heart failure: declining use and ongoing outcome trials - 11 month(s) ago
Digitalis glycosides (digoxin and digitoxin) are the oldest drugs in cardiovascular (CV) medicine and have generally been used in patients with heart failure (H
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
Digitalis in heart failure: declining use and ongoing outcome trials. #EHJ https://t.co/kct9TLUyFU #digoxin #HF #AF #trials #outcome #cardiotwitter @escardio @ESC_Journals https://t.co/LPsapg6TY4
-
How #Electronic #Medical #Record #Integration Can Support More Efficient #Critical #Care #Clinical #Trials https://t.co/9ATUOEGSif https://t.co/2b8lMHbtMR